RANDOMIZED CLINICAL TRIALS : revenue, balance sheet and financial ratios

RANDOMIZED CLINICAL TRIALS is a French company founded 36 years ago, specialized in the sector Conseil pour les affaires et autres conseils de gestion. Based in LYON (69002), this company of category PME shows in 2022 a revenue of 3.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - RANDOMIZED CLINICAL TRIALS (SIREN 351515762)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C 3 296 190 € 3 806 284 € 3 852 731 € 3 541 029 € 3 665 038 € 3 216 409 €
Net income 636 236 € 418 019 € 234 408 € 579 605 € 317 748 € 257 852 € 324 483 € 191 947 €
EBITDA N/C N/C -3 100 € 184 238 € 196 644 € 143 869 € 466 168 € 268 080 €
Net margin N/C N/C 7.1% 15.2% 8.2% 7.3% 8.9% 6.0%

Revenue and income statement

In 2024, RANDOMIZED CLINICAL TRIALS generates positive net income of 636 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 192 k€ -> 636 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

636 236 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 1%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 44%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.764%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

44.413%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

10.1%

Solvency indicators evolution
RANDOMIZED CLINICAL TRIALS

Sector positioning

Debt ratio
0.76 2024
2022
2023
2024
Q1: 0.0
Med: 3.98
Q3: 41.81
Good -45 pts over 3 years

In 2024, the debt ratio of RANDOMIZED CLINICAL TRIALS (0.76) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
44.41% 2024
2022
2023
2024
Q1: 4.2%
Med: 38.87%
Q3: 76.44%
Good +8 pts over 3 years

In 2024, the financial autonomy of RANDOMIZED CLINICAL TRIALS (44.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
2.42 years 2022
2022
Q1: 0.0 years
Med: 0.0 years
Q3: 1.02 years
Average

In 2022, the repayment capacity of RANDOMIZED CLINICAL TRIALS (2.42) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 367.66. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

367.656

Liquidity indicators evolution
RANDOMIZED CLINICAL TRIALS

Sector positioning

Liquidity ratio
367.66 2024
2022
2023
2024
Q1: 138.87
Med: 313.12
Q3: 966.61
Good

In 2024, the liquidity ratio of RANDOMIZED CLINICAL TRIALS (367.66) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
-222.84x 2022
2022
Q1: 0.0x
Med: 0.0x
Q3: 0.31x
Average

In 2022, the interest coverage of RANDOMIZED CLINICAL TRIALS (-222.8x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
RANDOMIZED CLINICAL TRIALS

Positioning of RANDOMIZED CLINICAL TRIALS in its sector

Comparison with sector Conseil pour les affaires et autres conseils de gestion

Valuation estimate

Based on 69 transactions of similar company sales in 2024, the value of RANDOMIZED CLINICAL TRIALS is estimated at 4 406 257 € (range 1 663 706€ - 11 030 109€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.

Estimated enterprise value 2024
69 tx
1663k€ 4406k€ 11030k€
4 406 257 € Range: 1 663 706€ - 11 030 109€
NAF 5 année 2024

Valuation method used

Net Income Multiple
636 236 € × 6.9x = 4 406 257 €
Range: 1 663 707€ - 11 030 110€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 69 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Conseil pour les affaires et autres conseils de gestion)

Compare RANDOMIZED CLINICAL TRIALS with other companies in the same sector:

Voir toutes les statistiques du secteur Conseil pour les affaires et autres conseils de gestion

Frequently asked questions about RANDOMIZED CLINICAL TRIALS

What is the revenue of RANDOMIZED CLINICAL TRIALS ?

The revenue of RANDOMIZED CLINICAL TRIALS in 2022 is 3.3 M€.

Is RANDOMIZED CLINICAL TRIALS profitable?

Yes, RANDOMIZED CLINICAL TRIALS generated a net profit of 636 k€ in 2024.

Where is the headquarters of RANDOMIZED CLINICAL TRIALS ?

The headquarters of RANDOMIZED CLINICAL TRIALS is located in LYON (69002), in the department Rhone.

Where to find the tax return of RANDOMIZED CLINICAL TRIALS ?

The tax return of RANDOMIZED CLINICAL TRIALS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does RANDOMIZED CLINICAL TRIALS operate?

RANDOMIZED CLINICAL TRIALS operates in the sector Conseil pour les affaires et autres conseils de gestion (NAF code 70.22Z). See the 'Sector positioning' section above to compare the company with its competitors.